

Rituxan (rituximab)
Truxima (rituximab-abbs)
Ruxience (rituximab-pvvr)
Riabni (rituximab-arrx)
Rituxan Hycela (rituximab and hyaluronidase)
Effective 06/05/2023

Plan	<input checked="" type="checkbox"/> MassHealth UPPL <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations			
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes. CD20 regulates cell cycle initiation; and, possibly, functions as a calcium channel. Rituximab binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity. B-cells are believed to play a role in the development and progression of rheumatoid arthritis. Signs and symptoms of rheumatoid arthritis are reduced by targeting B-cells and the progression of structural damage is delayed.

No PA	Require PA
	Riabni® (rituximab-arrx) Rituxan® (rituximab) Rituxan Hycela® (rituximab/hyaluronidase human) Ruxience® (rituximab-pvvr) Truxima® (rituximab-abbs)

Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with rituximab excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when the following criteria are met, and documentation is provided:

Riabni[®] (rituximab-arrx)

Rituxan[®] (rituximab)

Ruxience[®] (rituximab-pvvr)

Truxima[®] (rituximab-abbs)

Prescriber provides documentation of **ONE** of the following:

1. Diagnosis of Non-Hodgkin's Lymphoma (NHL)*
 - a. Appropriate dosing
2. Diagnosis of Rheumatoid Arthritis (RA)
 - a. Paid claims or physician attestation of inadequate response, adverse reaction or contraindication to **ONE** TNF antagonist
 - b. **ONE** of the following:
 - i. Paid claims within 30 days or physician attestation that the requested agent will be used in combination with methotrexate
 - ii. Contraindication or adverse reaction to methotrexate
 - c. Appropriate dosing
3. Diagnosis of induction therapy for Granulomatosis Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
 - a. Paid claims or physician attestation of inadequate response, adverse reaction or contraindication to cyclophosphamide
 - b. **ONE** of the following:
 - i. Paid claims within 30 days or physician attestation that the requested agent will be used in combination with a glucocorticoid
 - ii. Adverse reaction or contraindication to glucocorticoids
 - c. Appropriate dosing
4. Diagnosis of maintenance therapy for GPA or MPA
 - a. Appropriate dosing

*Appropriate diagnoses include:

- Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL using rituximab product as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL using rituximab product in combination with first line chemotherapy
- Follicular, CD20-positive, B-cell NHL, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy
- Non-progressing (including stable disease), low-grade, CD20- positive, B-cell NHL using rituximab product as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL using rituximab product in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.

Rituxan[®] (rituximab)

Prescriber provides documentation of **ONE** of the following:

1. Diagnosis of Pemphigus Vulgaris (PV)
 - a. **ONE** of the following:
 - i. Requested agent will be used in combination with systemic corticosteroids
 - ii. Paid claims (within the last 30 days) or physician attestation of inadequate response or adverse reaction to **ONE** or contraindication to **ALL** systemic corticosteroids
 - b. Appropriate dosing
2. Diagnosis of mature B-cell NHL or mature B-AL
 - a. Member is \geq six months and $<$ 18 years of age



- b. Physician attestation that the requested agent will be used in combination with systemic Lymphoma Malin B (LMB) chemotherapy (e.g., corticosteroids, vincristine, cyclophosphamide, methotrexate, cytarabine, doxorubicin, etoposide, and triple drug [methotrexate/cytarabine/corticosteroid] intrathecal therapy)
- c. Appropriate dosing

Rituxan Hycela® (rituximab/hyaluronidase human)

- 1. **ONE** of the following:
 - a. Diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL)*
 - b. Diagnosis of Follicular Lymphoma (FL)
- 2. Appropriate dosing

* For non-FDA-approved B-Cell lymphomas, Rituxan Hycela may be substituted for Rituxan if there is documentation that the member has received the first full dose of Rituxan by IV infusion

Riabni® (rituximab-arrx)

Rituxan® (rituximab)

Rituxan Hycela® (rituximab/hyaluronidase human)

Ruxience® (rituximab-pvvr)

Truxima® (rituximab-abbs)

- 1. Diagnosis of Chronic Lymphocytic Leukemia (CLL)
- 2. Appropriate dosing

Continuation of Therapy

Reauthorization requires physician documentation of improvement of member’s condition.

Limitations

- 1. Initial approvals will be granted for the following:
 - a. Non-Hodgkin’s Lymphoma (NHL) [including Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)] and Chronic Lymphocytic Leukemia (CLL), Pediatric patients with mature B-cell NHL and mature B-cell acute leukemia (B-AL): **6 months**
 - b. Rheumatoid arthritis (RA): **2 weeks of therapy with 4 month duration**
 - c. Pemphigus Vulgaris (PV): **2 weeks of therapy with 6 month duration**
 - d. Granulomatosis with Polyangiitis (GPA)/Microscopic Polyangiitis (MPA):
 - i. Induction (initial) therapy: 2 or 4 weeks of therapy depending on dosing requested with a **4 month duration**
 - ii. Maintenance (subsequent) therapy: **1 week of therapy with 4 month or 6 month duration**
- 2. Reauthorizations will be granted for the following:
 - a. Non-Hodgkin’s Lymphoma (NHL) [including Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)] and Chronic Lymphocytic Leukemia (CLL), Pediatric patients with mature B-cell NHL and mature B-cell acute leukemia (B-AL): **12 months**
 - b. Rheumatoid arthritis (RA): **6 weeks of therapy with 12 month duration**
 - c. Pemphigus Vulgaris (PV): **2 weeks of therapy with 12 month duration**
 - d. Granulomatosis with Polyangiitis (GPA)/Microscopic Polyangiitis (MPA): **3 week of therapy with 12 month duration**

Appendix

Examples of contraindications to methotrexate



1. Alcoholism, alcoholic liver disease or other chronic liver disease
2. Breastfeeding
3. Blood dyscrasias (e.g., thrombocytopenia, leukopenia, significant anemia)
4. Elevated liver transaminases
5. History of intolerance or adverse event
6. Hypersensitivity
7. Interstitial pneumonitis or clinically significant pulmonary fibrosis
8. Myelodysplasia
9. Pregnancy or planning pregnancy (male or female)
10. Renal impairment
11. Significant drug interaction

Off-Label Uses for Rituximab Products

- Requests may be approvable if conventional therapies have failed (i.e. inadequate response, adverse reaction and/or contraindications)
- Prior authorization requests for any of the following conditions should include details of previous “conventional” therapy trials before the approval of rituximab

Off-Label Use	Approval Criteria
Autoimmune Encephalitis	<p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of autoimmune encephalitis (also includes anti-NMDA receptor encephalitis) 2. Paid claims (within the last 30 days) or physician attestation of inadequate response or adverse reaction to ONE or contraindication to ALL of the following: <ol style="list-style-type: none"> a. intravenous glucocorticoids b. intravenous immune globulin c. plasma exchange 3. Paid claims (within the last 30 days) or physician attestation of inadequate response, adverse reaction, or contraindication to cyclophosphamide
Autoimmune Epilepsy	<p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of autoimmune epilepsy 2. Paid claims (within the last 30 days) or physician attestation of inadequate response or adverse reaction to ONE or contraindication to ALL of the following: <ol style="list-style-type: none"> a. intravenous glucocorticoids b. intravenous immune globulin c. plasma exchange 3. Paid claims (within the last 30 days) or physician attestation of inadequate response or adverse reaction to ONE or contraindication to ALL of the following: <ol style="list-style-type: none"> a. azathioprine b. cyclophosphamide c. mycophenolate
Post-Transplantation Lymphoproliferative Disease (PTLD)	<p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Appropriate diagnosis



Waldenström's macroglobulinemia (WM)	Prescriber provides documentation of ALL of the following: 1. Appropriate diagnosis
Idiopathic membranous nephropathy (IMN)	Prescriber provides documentation of ALL of the following: 1. Appropriate diagnosis 2. Paid claims or physician attestation of inadequate response, adverse reaction to ONE of the following or contraindication to BOTH of the following: a. cyclophosphamide b. chlorambucil 3. Paid claims or physician attestation of inadequate response, adverse reaction to ONE of the following or contraindication to BOTH of the following: a. cyclosporine b. tacrolimus
Lupus nephritis (LN)	Prescriber provides documentation of ALL of the following: 1. Appropriate diagnosis 2. Paid claims or physician attestation of inadequate response, adverse reaction, or contraindication to BOTH of the following: a. cyclophosphamide b. mycophenolate
Autoimmune Hemolytic Anemia (AIHA)	Prescriber provides documentation of ALL of the following: 1. Appropriate diagnosis 2. Paid claims or physician attestation of inadequate response or adverse reaction to ONE or contraindication to ALL corticosteroids
Moderate-to-Severe Cryoglobulinemia Syndrome	Prescriber provides documentation of ALL of the following: 1. Diagnosis of moderate to severe cryoglobulinemia syndrome 2. Requested agent will be used in combination with systemic glucocorticoids
Graft Versus Host Disease (GVHD)	Prescriber provides documentation of ALL of the following: 1. Appropriate diagnosis 2. Inadequate response, or adverse reaction to ONE or contraindication to ALL corticosteroids 3. Paid claims or physician attestation of inadequate response or adverse reaction to TWO of the following or contraindication to ALL of the following: a. abatacept b. alemtuzumab c. belumosudil d. cyclosporine e. etanercept f. everolimus g. hydroxychloroquine h. ibrutinib i. imatinib j. methotrexate k. mycophenolate mofetil



	<ul style="list-style-type: none"> l. ruxolitinib m. sirolimus n. tacrolimus o. temsirolimus
Idiopathic Thrombocytopenia Purpura (ITP)	<p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Appropriate diagnosis 2. Paid claims or physician attestation of inadequate response or adverse reaction to ONE or contraindication to ALL corticosteroids
Neuromyelitis Optica Spectrum Disorders (NMOSD) maintenance therapy	<p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Appropriate diagnosis 2. Paid claims or physician attestation of inadequate response or adverse reaction to ONE or contraindication to BOTH of the following: <ul style="list-style-type: none"> a. azathioprine b. mycophenolate
Thrombotic Thrombocytopenia Purpura (TTP)	<p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Appropriate diagnosis 2. ONE of the following: <ul style="list-style-type: none"> a. Member underwent plasma exchange b. Clinical rationale as to why plasma exchange was not performed 3. Paid claims or physician attestation of inadequate response, adverse reaction, or contraindication to corticosteroids
Systemic Lupus Erythematosus (SLE)	<p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Appropriate diagnosis 2. Paid claims or physician attestation of inadequate response or adverse reaction to TWO of the following OR contraindication to ALL of the following: <ul style="list-style-type: none"> a. azathioprine b. cyclophosphamide c. cyclosporine d. leflunomide e. methotrexate f. mycophenolate
Multiple Sclerosis	<p><u>Relapsing-Remitting MS (RRMS)</u></p> <p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Appropriate diagnosis 2. Prescriber is a neurologist or consult notes from a neurology office are provided
IgG-related disease	<p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Appropriate diagnosis 2. Paid claims or physician attestation of inadequate response or adverse reaction to ONE or contraindication to ALL glucocorticoids
Minimal change disease	<p>Prescriber provides documentation of ALL of the following:</p>



	<ol style="list-style-type: none"> 1. Appropriate diagnosis 2. Paid claims or physician attestation of inadequate response, adverse reaction, or contraindication to BOTH of the following: <ol style="list-style-type: none"> a. cyclophosphamide b. cyclosporine
Polymyositis (PM) and Dermatomyositis (DM)	<p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Appropriate diagnosis 2. Paid claims or physician attestation of inadequate response or adverse reaction to ONE or contraindication to ALL corticosteroids 3. Paid claims or physician attestation of inadequate response or adverse reaction to TWO of the following or contraindication to ALL of the following: <ol style="list-style-type: none"> a. azathioprine b. cyclophosphamide c. cyclosporine d. methotrexate
Myasthenia Gravis, Generalized (MG)	<p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of generalized MG 2. Paid claims (within the last 30 days) or physician attestation of inadequate response, adverse reaction, or contraindication to pyridostigmine 3. Paid claims (within the last 30 days) or physician attestation of inadequate response or adverse reaction to ONE or contraindication to ALL corticosteroids 4. ONE of the following: <ol style="list-style-type: none"> a. Member has muscle-specific tyrosine kinase (MuSK)-positive MG (MuSK-positive MG) b. Paid claims (within the last 30 days) or physician attestation of inadequate response or adverse reaction to ONE or contraindication ALL of the following: <ol style="list-style-type: none"> i. azathioprine ii. cyclophosphamide iii. cyclosporine iv. eculizumab v. efgartigimod vi. intravenous immune globulin vii. mycophenolate viii. ravulizumab ix. tacrolimus
Pemphigus Foliaceus (PF)	<p>Prescriber provides documentation of ALL of the following:</p> <ol style="list-style-type: none"> 1. Diagnosis of PF 2. ONE of the following: <ol style="list-style-type: none"> a. Requested agent will be used in combination with systemic glucocorticoids



	<p>b. Paid claims (within the last 30 days) or physician attestation of inadequate response or adverse reaction to ONE or contraindication to ALL systemic corticosteroids</p> <p>3. Appropriate dosing (refer to FDA-approved dosing for PV)</p>
Off-label approval durations	<p>Initial: 3 months</p> <p>Recertification: 12 months</p>

References

1. Rituxan [package insert]. South San Francisco, CA: Genentech, Inc.; October 2018.
2. DRUGDEX® System [Internet database]. Ann Arbor, MI: Truven Health Analytics. Updated periodically. Accessed November 19, 2018.
3. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a double blind, placebo-controlled study. *Ann Rheum Dis*. 2008;67:1541-1544.
4. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2010;62(4):960-8.
5. Smolen JS, Landewé R, Billsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*. 2017;0:1-18.
6. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol*. 2016;68(1):1-26.
6. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum*. 2008;59(6):762-784.
7. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N Engl J Med*. 2008;358:676-688.
8. Scott, T.F., Frohman, E.M., DeSeze, J., (2011). Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *American Academy of Neurology*. 77: 2128-2134.
9. Trebst, C., Jarius, S., et al. (2014). Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). *J Neurol* 261: 1-16.
10. Micromedex Solutions [database online]. Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/>. Accessed April 17, 2019.
11. The NCCN Drugs & Biologics Compendium® © 2019 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed April 17, 2019.
12. Arber D, Orazi A, Vardiman J, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. May 19, 2016;127(20):2391-2405.
13. The NCCN Clinical Practice Guidelines in Oncology® Acute Lymphoblastic Leukemia (Version 1.2019). © 2019 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed April 17, 2019.
14. Lexicomp Online®, AHFS® Drug Information, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; <http://online.lexi.com> [available with subscription]. Accessed April 17, 2019.
15. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transplant*. 2009; 15(10):1143-1238. URL: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103296/pdf/nihms205400.pdf>. Accessed April 30, 2019.
16. Riabni (rituximab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; December 2020.

Review History

12/16/2019 – add Truxima to criteria



03/18/2020 – Reviewed and switched from SGM to custom criteria; combine Rituxan Oncology and Rituxan RA + Other Conditions (effective 6/1/20)

11/18/2020 – separated out MH vs. Comm/Exch

05/19/2021 – Updated and Reviewed for May P&T; added Riabni and Rituxan Hycela to criteria

02/08/2023 - Reviewed and updated for Feb P&T. Matched MH UPPL criteria to be in compliance with Masshealth unified formulary requirements. Added Off-Label indications to appendix. Clarified approval durations. Effective 4/1/23.

05/10/23 – Reviewed and updated for P&T. A note was added underneath approval criteria for NHL to clarify the subtypes of NHL for which rituximab agents are FDA-approved. The criteria for PV were updated to remove the trial requirement with systemic immunosuppressive therapy as initial therapy with a steroid and rituximab is now preferred. Off-label criteria for GVHD updated to remove thalidomide from the acceptable trials and to add several agents as acceptable trials, as recommended by NCCN. Criteria for ITP updated to remove required splenectomy trial. Several new off label indications were added to the policy. Effective 6/5/23.

